A Phase 3, Multicenter, randomised, double-blind, placebo controlled trial to evaluate the efficacy and safety of Navenibart in participants with Hereditary Angioedema (NCT06842823)

Alpha Orbit - STAR0215-301

This trial is Coming soon
Registration number NCT06842823
Navenibart is being developed as a prophylactic treatment for the prevention of Hereditary Angioedema attacks.

Program & service

This trial is being run with the Heart & Lung service, and as part of the Respiratory program.

Trial phase

Phase 3

Trial participation type

This trial has been designed for the Clinical Research of a Drug.

Principal investigator

A/Prof Celia Zubrinich

Key inclusion data

Documented diagnosis of HAE Type 1 or Type 2. Lab findings consistent with HAE Type 1 or 2. Documented clinical history consistent with HAE.

More information

To find out more about this clinical trial, please review full details on the ANZCTR website.

View on ANZCTR

If you would like further details or have any questions about this clinical trial, we encourage you to get in touch with us and a member of our team will be happy to provide you with more information.